

CITATION REPORT

List of articles citing

Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials

DOI: 10.1111/dom.13353

Diabetes, Obesity and Metabolism, 2018, 20, 2210-2219.

Source: <https://exaly.com/paper-pdf/71049533/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
64	Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 2210-2219	6.7	44
63	Consensus Recommendations on GLP-1 RA Use in the Management of Type 2 Diabetes Mellitus: South Asian Task Force. <i>Diabetes Therapy</i> , 2019 , 10, 1645-1717	3.6	17
62	Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials. <i>Diabetes and Metabolism</i> , 2019 , 45, 409-418	5.4	54
61	Will medications that mimic gut hormones or target their receptors eventually replace bariatric surgery?. <i>Metabolism: Clinical and Experimental</i> , 2019 , 100, 153960	12.7	12
60	Mechanism of Glucagon-Like Peptide 1 Improvements in Type 2 Diabetes Mellitus and Obesity. <i>Current Obesity Reports</i> , 2019 , 8, 284-291	8.4	14
59	Of mice and men: Why progress in the pharmacological management of obesity is slower than anticipated and what could be done about it?. <i>Metabolism: Clinical and Experimental</i> , 2019 , 96, vi-xi	12.7	4
58	The Discovery and Development of Liraglutide and Semaglutide. <i>Frontiers in Endocrinology</i> , 2019 , 10, 155	5.7	181
57	Semaglutide as a promising antiobesity drug. <i>Obesity Reviews</i> , 2019 , 20, 805-815	10.6	33
56	Pharmacotherapy of obesity: Available medications and drugs under investigation. <i>Metabolism: Clinical and Experimental</i> , 2019 , 92, 170-192	12.7	98
55	Efficacy and Safety of Semaglutide for Type 2 Diabetes by Race and Ethnicity: A Post Hoc Analysis of the SUSTAIN Trials. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	9
54	A review of GLP-1 receptor agonists in type 2 diabetes: A focus on the mechanism of action of once-weekly agents. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2020 , 45 Suppl 1, 17-27	2.2	16
53	Corrination of a GLP-1 Receptor Agonist for Glycemic Control without Emesis. <i>Cell Reports</i> , 2020 , 31, 107768	10.6	9
52	Impact of patient characteristics on efficacy and safety of once-weekly semaglutide versus dulaglutide: SUSTAIN 7 analyses. <i>BMJ Open</i> , 2020 , 10, e037883	3	3
51	Bariatric surgery for the treatment of chronic kidney disease in obesity and type 2 diabetes mellitus. <i>Nature Reviews Nephrology</i> , 2020 , 16, 709-720	14.9	28
50	Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events. <i>BMJ Open Diabetes Research and Care</i> , 2020 , 8,	4.5	11
49	Weight-centric pharmacological management of type 2 diabetes mellitus - An essential component of cardiovascular disease prevention. <i>Journal of Diabetes and Its Complications</i> , 2020 , 34, 107619	3.2	7
48	Bariatric and metabolic surgery during and after the COVID-19 pandemic: DSS recommendations for management of surgical candidates and postoperative patients and prioritisation of access to surgery. <i>Lancet Diabetes and Endocrinology</i> , 2020 , 8, 640-648	18.1	94

47	Increased insulin receptor binding and increased IGF-1 receptor binding are linked with increased growth of L6hIR cell xenografts in vivo. <i>Scientific Reports</i> , 2020 , 10, 7247	4.9	1
46	The Implication of Gut Hormones in the Regulation of Energy Homeostasis and Their Role in the Pathophysiology of Obesity. <i>Current Obesity Reports</i> , 2020 , 9, 255-271	8.4	12
45	Evaluation of Characteristics of Gastrointestinal Adverse Events with Once-Weekly Dulaglutide Treatment in Chinese Patients with Type 2 Diabetes: A Post Hoc Pooled Analysis of Two Randomized Trials. <i>Diabetes Therapy</i> , 2020 , 11, 1821-1833	3.6	3
44	Approach to the Patient: Management of the Post-Bariatric Surgery Patient With Weight Regain. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 , 106, 251-263	5.6	8
43	A genetic map of the mouse dorsal vagal complex and its role in obesity. <i>Nature Metabolism</i> , 2021 , 3, 530-545	14.6	17
42	Aversion to Off-label Prescribing in Clinical Pediatric Weight Management: The Quintessential Double Standard. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 , 106, 2103-2113	5.6	1
41	The Role of GIP in the Regulation of GLP-1 Satiety and Nausea. <i>Diabetes</i> , 2021 , 70, 1956-1961	0.9	5
40	Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity. <i>Expert Opinion on Emerging Drugs</i> , 2021 , 26, 231-243	3.7	10
39	Safety of Semaglutide. <i>Frontiers in Endocrinology</i> , 2021 , 12, 645563	5.7	7
38	Strengthening Semaglutide-GLP-1R Binding Affinity via a Val27-Arg28 Exchange in the Peptide Backbone of Semaglutide: A Computational Structural Approach. <i>Journal of Computational Biophysics and Chemistry</i> , 2021 , 20, 495-499		1
37	Glucagon-like peptide-1 in diabetes care: Can glycaemic control be achieved without nausea and vomiting?. <i>British Journal of Pharmacology</i> , 2021 ,	8.6	3
36	Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy and Body Weight in Adults With Overweight or Obesity-Reply. <i>JAMA - Journal of the American Medical Association</i> , 2021 , 326, 1214-1215	27.4	15
35	Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. <i>Diabetes, Obesity and Metabolism</i> , 2022 , 24, 94-105	6.7	2
34	Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5. <i>Obesity</i> , 2020 , 28, 1050-1061	8	77
33	New-generation anti-obesity drugs: naltrexone/bupropion and liraglutide. An update for endocrinologists and nutritionists. <i>Minerva Endocrinologica</i> , 2020 , 45, 127-137	1.9	12
32	Novel Non-invasive Approaches to the Treatment of Obesity: From Pharmacotherapy to Gene Therapy. <i>Endocrine Reviews</i> , 2021 ,	27.2	4
31	The role of anti-obesity drugs in the management of obese diabetics. <i>Medicinski Glasnik Specijalne Bolnice Za Bolesti Vitaste Uezde I Bolesti Metabolizma Zlatibor</i> , 2018 , 23, 15-21	0	
30	Wegovy (semaglutide): a new weight loss drug for chronic weight management. <i>Journal of Investigative Medicine</i> , 2021 ,	2.9	8

29	Real-world weight loss with diabetes medications: But is it actually real?. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2021 ,	1.7	
28	Pragmatic Weight Management Program for Patients With Obesity and Heart Failure With Preserved Ejection Fraction. <i>Journal of the American Heart Association</i> , 2021 , 10, e022930	6	1
27	SEMAGLUTIDE FOR WEIGHT LOSS. <i>Cardiology in Review</i> , 2022 , Publish Ahead of Print,	3.2	0
26	Treatment of Obesity in the Patient with Type 2 Diabetes. 2022 , 451-459		
25	Adjunctive Therapy, Including Pharmacotherapy. 2022 , 279-296		
24	Efficacy and safety of oral semaglutide by subgroups of patient characteristics in the PIONEER phase 3 programme.. <i>Diabetes, Obesity and Metabolism</i> , 2022 ,	6.7	2
23	Precision Medicine for Diabetes and Dyslipidemia. 2022 , 65-87		
22	Once-Weekly Semaglutide Induces an Early Improvement in Body Composition in Patients with Type 2 Diabetes: A 26-Week Prospective Real-Life Study. <i>Nutrients</i> , 2022 , 14, 2414	6.7	0
21	Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice. <i>Molecular Metabolism</i> , 2022 , 101533	8.8	1
20	Type 2 diabetics followed up by family physicians: Treatment sequences and changes over time in weight and glycated hemoglobin. <i>Primary Care Diabetes</i> , 2022 ,	2.4	
19	Who knew? PPARs may act in the brain too. 2022 , 4, 965-966		
18	Gastrointestinal adverse events of semaglutide in patients with overweight or obesity. 2022 ,		
17	Efficacy and safety of semaglutide on weight loss in obese or overweight patients without diabetes: A systematic review and meta-analysis of randomized controlled trials. 13,		0
16	Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system. 10,		1
15	Characterization of Low-Level D-amino acid Isomeric Impurities of Semaglutide Using Liquid Chromatography-High Resolution Tandem Mass Spectrometry. 2022 , 115164		0
14	Obesity pharmacotherapy: incretin action in the central nervous system. 2023 , 44, 50-63		0
13	Evaluating Weight Loss With Semaglutide in Elderly Patients With Type II Diabetes. 875512252211374		0
12	A phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of danuglipron (PF-06882961), an oral small-molecule glucagon-like peptide-1 receptor agonist, in Japanese adults with type 2 diabetes mellitus.		0

- 11 Early type 2 diabetes treatment intensification with glucagon-like peptide-1 receptor agonists in primary care: an Australian perspective on guidelines and the global evidence. ○
- 10 Body weight loss with oral semaglutide is mediated predominantly by effects other than gastrointestinal adverse events in patients with type 2 diabetes: a post hoc analysis. ○
- 9 Obesity and diabetes: the final frontier. 1
- 8 Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus. **2023**, 12, 145 ○
- 7 Effects of a Dulaglutide plus Calorie-Restricted Diet versus a Calorie-Restricted Diet on Visceral Fat and Metabolic Profiles in Women with Polycystic Ovary Syndrome: A Randomized Controlled Trial. **2023**, 15, 556 ○
- 6 Glucagon-Like Peptide 1 Therapy: From Discovery to Type 2 Diabetes and Beyond. **2023**, 38, 25-33 ○
- 5 The postprandial actions of GLP-1 receptor agonists: The missing link for cardiovascular and kidney protection in type 2 diabetes. **2023**, 35, 253-273 ○
- 4 Hormonal GutBrain Signaling for the Treatment of Obesity. **2023**, 24, 3384 ○
- 3 Impact of BMI and comorbidities on efficacy of once-weekly semaglutide: Post hoc analyses of the STEP 1 randomized trial. **2023**, 31, 990-999 ○
- 2 A proposal from the Liver Forum for the management of comorbidities in nonalcoholic steatohepatitis therapeutic trials. **2023**, ○
- 1 A Comprehensive Review on Weight Loss Associated with Anti-Diabetic Medications. **2023**, 13, 1012 ○